Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma

NCT04143984 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

146

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Induction chemotherapy
RADIATION: Carbon-ion radiotherapy
DRUG: Camrelizumab

Sponsor

Shanghai Proton and Heavy Ion Center